Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : ALTA NATURAL HERBS & SUPPLEMENTS LTD. (AHS-ASE) -- Ignore unavailable to you. Want to Upgrade?

To: Robert G. Hanah who wrote (18)	10/19/1998 12:54:00 PM
From: K. Anders	Read Replies (1) \| Respond to of 66

Hey, here's more news to drive the stock: Good News! ALTA NATURAL HERBS & SUPPLEMENTS LTD. (AHS:ASE) #1148 20800 Westminster Highway, Richmond, BC V6V 2W3 MEDIA RELEASE Hepatico Results In Hepatitis-C sufferers benefit from naturopathic treatment For immediate release 12:01 AM Monday October 19, 1998 Vancouver, B.C. Company President, Adolf Huckschlag, reports that preliminary test data has been received that indicates The Companys Hepatitis-C treatment, Hepatico, is having a positive effect on sufferers in their test group. "We are seeing a reduction of fatigue and nausea, normalization of digestive functions as well as improvements in sleeping and eating habits." According to Dr. David Khoupenia, Alta Naturals study coordinator. The data, which represents a 60-day or less treatment regimen for the study participants, indicates statistically significant reductions in ALT and AST liver enzyme measurements. Although the results have not been fully compiled and published, enzyme reduction over the 60 day period range from 0% to 78% with most patients experiencing reductions. "These results," said Khoupenia, "although not conclusive at this point, when interpreted in light of favourable physical improvements noted by a majority of sufferers, indicate that Hepatico may be highly beneficial to those suffering from this fatal disease." These results are the first to be received from this nine-month study of the efficacy of Hepatico in alleviating the suffering and debilitating symptoms associated with infection from the Hepatitis-C virus. There are currently few effective options for the 170,000,000 people suffering from Hep-C. Unlike Hepatico which is atoxic, most effective drug-based treatments are highly toxic and can be extremely debilitating, to the point of causing death in some patients. The Company will release detailed preliminary results as soon as they are available. This is the final step in The Companys assessment of the healing value and market potential of this naturopathic treatment. The Company is also in possession of 17 clinical and pre-clinical trials conducted in Europe on Hepatico between 1992 and 1996. The conclusions of those studies will be compared with these preliminary in-house tests and an announcement with respect to Alta Naturals plans for this treatment will be made in two news conferences to be conducted in Canada and The United States. The exact time and location of these announcements will be determined within days. -30- Information: Raymond J. Irvine Vice President Finance Local Vancouver 604.689.0087 Toll Free 1.800.969.7222 altanat@axionet.com <http://www.alta-natural.com/>www.alta-natural.com The Alberta Stock Exchange has neither approved nor disapproved of the contents of this release.